| Literature DB >> 27100566 |
Alberto Purwada1, Ye F Tian2, Weishan Huang3, Kathleen M Rohrbach4, Simrita Deol3, Avery August3, Ankur Singh2.
Abstract
Soluble antigen-based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose-limiting systemic toxicity. A versatile, immunomodulatory, self-assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials-based safer immunotherapy approaches.Entities:
Keywords: T cell; antigen; immunomodulation; immunotherapy; nanogels
Mesh:
Substances:
Year: 2016 PMID: 27100566 PMCID: PMC5532174 DOI: 10.1002/adhm.201501062
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933